Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135029 · ClinicalTrials.gov registry record · Phase 3
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT02135029: Completed Phase 3 study, sponsored by Pfizer.
NCT02135029 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 184 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02135029, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.
Interventions
- DRUG Atorvastatin
- DRUG Bococizumab (PF-04950615;RN316)
- OTHER Placebo for Bococizumab (PF-04950615;RN316)
- OTHER Placebo for atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
What the finished NCT02135029 record still lists
NCT02135029 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 4 interventions - of which Atorvastatin is the first listed.
NCT02135029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02135029 about?
NCT02135029 is a clinical study titled "Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins". This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.
What is the current status of trial NCT02135029?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2014-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02135029?
The interventions under investigation include: Atorvastatin (DRUG), Bococizumab (PF-04950615;RN316) (DRUG), Placebo for Bococizumab (PF-04950615;RN316) (OTHER), Placebo for atorvastatin (OTHER).
Who is sponsoring clinical trial NCT02135029?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02135029's enrollment target sits among peer trials
184 1418th of 2000 higher than 581 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia